Inducing Potent and Durable T Cell Responses to Fight Disease episode artwork

EPISODE · Jun 21, 2023 · 16 MIN

Inducing Potent and Durable T Cell Responses to Fight Disease

from The Bio Report · host Levine Media Group

Vaccitech first gained attention as co-inventor of the Covid-19 vaccine licensed to AstraZeneca. The University of Oxford spin-out is developing a pipeline of T cell immunotherapies to treat and cure chronic infectious diseases, autoimmune diseases, and cancers. The company’s lead experimental therapy is a potentially curative monotherapy for chronic hepatitis B viral infection. We spoke to Bill Enright, CEO of Vaccitech, about the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.

Bill Enright, CEO of Vaccitech, discusses the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.

NOW PLAYING

Inducing Potent and Durable T Cell Responses to Fight Disease

0:00 16:57

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Bio Report?

This episode is 16 minutes long.

When was this The Bio Report episode published?

This episode was published on June 21, 2023.

What is this episode about?

Vaccitech first gained attention as co-inventor of the Covid-19 vaccine licensed to AstraZeneca. The University of Oxford spin-out is developing a pipeline of T cell immunotherapies to treat and cure chronic infectious diseases, autoimmune diseases,...

Can I download this The Bio Report episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!